Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The President and Plan B

This article was originally published in The Tan Sheet

Executive Summary

President Bush's sentiments about birth control are "directly at odds with FDA's extraordinary refusal to approve OTC sale of emergency contraception products," according to letter to the President sent by the Center for Reproductive Rights July 6. The letter refers to a recent statement by the Bush administration that the President supports the "availability of safe and effective products and services to assist responsible adults in making decisions about preventing or delaying conception." The administration's position on birth control was requested by Members of Congress in July 2005. The reasons for delaying an answer to Barr Labs' Plan B switch application "appear to have nothing to do with the safety or effectiveness of Plan B - the only considerations that are the proper purview of the FDA," CRR maintains. "If the administration indeed supports safe and effective products and services to assist responsible adults...then there is no reason for its failure to support the availability of EC"...

You may also be interested in...

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.

What’s Next? Five Things To Look Out For In March

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts